Consistently, it has been described that, in contrast to EVs from MM patients, EVs from the bone marrow MSCs of healthy donors decrease the viability, proliferation, and migration of MM cells via the activation of a mitogen-activated protein kinase (MAPK) pathway [85]. The gene discussed is WNK2; the disease is Miyoshi myopathy.